 |
|
Phase I-II Study of Advanced Head and Neck Squamous Cell Carcinoma Patients Treated With Recombinant Human Interferon Gamma
William J. Richtsmeier, MD, PhD;
William M. Koch, MD;
William P. McGuire, MD;
Michael E. Poole;
Esther H. Chang, PhD
Arch Otolaryngol Head Neck Surg. 1990;116(11):1271-1277.
Abstract
| |
• The association of immunodeficiency with head and neck squamous cell carcinoma has generated the concept of supplying immunologically active agents as a means of treating these cancers. One of the most active immunologic messengers is interferon gamma, which has been observed in our laboratories to also have a direct cytotoxic effect on cultures of squamous cell carcinoma derived from the head and neck. To test the feasibility of treating patients with advanced but resectable head and neck cancer with this agent, we designed a phase I-II trial of recombinant human interferon gamma using a 24-hour infusion repeated weekly for four times. In this study, both tumor and immunologic parameters were studied before and after treatment. Eight patients were entered into the study with the highest recombinant human interferon gamma dose attempted being 0.25 mg/m2 per 24 hours. Minimal side effects were observed. Three patients had clinically measurable responses, four had stabilization of disease, and one had progression while receiving treatment. Histopathologic results of treatment were similar to in vitro observations. Necrosis, as well as differentiation of tumor cells, was observed. In some tumors there was a marked decrease in cellularity without a change in tumor volume due to increased extracellular keratin deposition. Our study indicates that evaluation of adoptive immunotherapy trials in head and neck cancer needs to include parameters other than simple tumor regression as an end point, otherwise therapeutically important lymphokine-induced changes may be missed. Further evaluation of recombinant human interferon gamma and agents that induce human interferon gamma are warranted.
(Arch Otolaryngol Head Neck Surg. 1990;116:1271-1277)
Author Affiliations
From the Departments of Otolaryngology-Head Neck Surgery (Drs Richtsmeier, Koch, and McGuire), and Oncology (Drs Richtsmeier and McGuire, and Mr Poole), The Johns Hopkins Medical Institutions, Baltimore, Md, and the Department of Pathology, Uniformed Services University of the Health Sciences, Bethesda, Md (Dr Chang).
Footnotes
Accepted for publication August 7, 1990.
Read before the American Society for Head and Neck Surgery, Palm Beach, Fla, April 30, 1990.
Reprint requests to Carnegie 469, Department of Otolaryngology-Head Neck Surgery, The Johns Hopkins Medical Institutions, 600 N Wolfe St, Baltimore, MD 21205 (Dr Richtsmeier).
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Immune Escape Associated with Functional Defects in Antigen-Processing Machinery in Head and Neck Cancer.
Ferris et al.
Clin. Cancer Res. 2006;12:3890-3895.
ABSTRACT
| FULL TEXT
Systemic Adoptive T-Cell Immunotherapy in Recurrent and Metastatic Carcinoma of the Head and Neck: A Phase 1 Study
To et al.
Arch Otolaryngol Head Neck Surg 2000;126:1225-1231.
ABSTRACT
| FULL TEXT
Interferon Gamma Enhances Lymphokine-Activated Killer Cell Adhesion but Not Lysis of Head and Neck Squamous Cell Carcinoma
Scher et al.
Arch Otolaryngol Head Neck Surg 1995;121:1271-1275.
ABSTRACT
Growth Inhibition by Interferon Beta and Gamma of MDA 886Ln Monolayer Cells and Multicellular Tumor Spheroids: A Differentiation Therapy Model for Squamous Cell Carcinoma
Sacks et al.
Arch Otolaryngol Head Neck Surg 1994;120:1267-1272.
ABSTRACT
Induction of the Intercellular Adhesion Molecule (ICAM-1) on Squamous Cell Carcinoma by Interferon Gamma
Scher et al.
Arch Otolaryngol Head Neck Surg 1993;119:432-438.
ABSTRACT
|
